Apoptosis_NN
and_CC
growth_NN
inhibition_NN
in_IN
malignant_JJ
lymphocytes_NNS
after_IN
treatment_NN
with_IN
arsenic_JJ
trioxide_NN
at_IN
clinically_RB
achievable_JJ
concentrations_NNS
-LCB-_-LRB-
see_VB
comments_NNS
-RCB-_-RRB-

BACKGROUND_NN
:_:
Arsenic_JJ
trioxide_NN
-LRB-_-LRB-
As2O3_NN
-RRB-_-RRB-
can_MD
induce_VB
clinical_JJ
remission_NN
in_IN
patients_NNS
with_IN
acute_JJ
promyelocytic_JJ
leukemia_NN
via_IN
induction_NN
of_IN
differentiation_NN
and_CC
programmed_VBN
cell_NN
death_NN
-LRB-_-LRB-
apoptosis_NN
-RRB-_-RRB-
._.

We_PRP
investigated_VBD
the_DT
effects_NNS
of_IN
As2O3_NN
on_IN
a_DT
panel_NN
of_IN
malignant_JJ
lymphocytes_NNS
to_TO
determine_VB
whether_IN
growth-inhibitory_JJ
and_CC
apoptotic_JJ
effects_NNS
of_IN
As2O3_NN
can_MD
be_VB
observed_VBN
in_IN
these_DT
cells_NNS
at_IN
clinically_RB
achievable_JJ
concentrations_NNS
._.

METHODS_NNS
:_:
Eight_CD
malignant_JJ
lymphocytic_JJ
cell_NN
lines_NNS
and_CC
primary_JJ
cultures_NNS
of_IN
lymphocytic_JJ
leukemia_NN
and_CC
lymphoma_NN
cells_NNS
were_VBD
treated_VBN
with_IN
As2O3_NN
,_,
with_IN
or_CC
without_IN
dithiothreitol_NN
-LRB-_-LRB-
DTT_NN
-RRB-_-RRB-
or_CC
buthionine_NN
sulfoximine_NN
-LRB-_-LRB-
BSO_NN
-RRB-_-RRB-
-LRB-_-LRB-
an_DT
inhibitor_NN
of_IN
glutathione_NN
synthesis_NN
-RRB-_-RRB-
._.

Apoptosis_NN
was_VBD
assessed_VBN
by_IN
cell_NN
morphology_NN
,_,
flow_NN
cytometry_NN
,_,
annexin_NN
V_NN
protein_NN
level_NN
,_,
and_CC
terminal_JJ
deoxynucleotidyl_NN
transferase_NN
labeling_NN
of_IN
DNA_NN
fragments_NNS
._.

Cellular_JJ
proliferation_NN
was_VBD
determined_VBN
by_IN
5-bromo-2_NN
'_POS
-_JJ
deoxyuridine_NN
incorporation_NN
into_IN
DNA_NN
and_CC
flow_NN
cytometry_NN
and_CC
by_IN
use_NN
of_IN
a_DT
mitotic_JJ
arrest_NN
assay_NN
._.

Mitochondrial_JJ
transmembrane_JJ
potential_NN
-LRB-_-LRB-
delta_NN
psi_NN
-LRB-_-LRB-
m_NN
-RRB-_-RRB-
-RRB-_-RRB-
was_VBD
measured_VBN
by_IN
means_NNS
of_IN
rhodamine_NN
123_CD
staining_NN
and_CC
flow_NN
cytometry_NN
._.

Protein_NN
expression_NN
was_VBD
assessed_VBN
by_IN
western_NN
blot_NN
analysis_NN
or_CC
immunofluorescence_NN
._.

RESULTS_NNS
:_:
Therapeutic_JJ
concentrations_NNS
of_IN
As2O3_NN
-LRB-_-LRB-
1-2_CD
microM_NN
-RRB-_-RRB-
had_VBD
dual_JJ
effects_NNS
on_IN
malignant_JJ
lymphocytes_NNS
:_:
1_LS
-RRB-_-RRB-
inhibition_NN
of_IN
growth_NN
through_IN
adenosine_NN
triphosphate_NN
-LRB-_-LRB-
ATP_NN
-RRB-_-RRB-
depletion_NN
and_CC
prolongation_NN
of_IN
cell_NN
cycle_NN
time_NN
and_CC
2_LS
-RRB-_-RRB-
induction_NN
of_IN
apoptosis_NN
._.

As2O3-induced_JJ
apoptosis_NN
was_VBD
preceded_VBN
by_IN
delta_NN
psi_NN
-LRB-_-LRB-
m_NN
-RRB-_-RRB-
collapse_NN
._.

DTT_NN
antagonized_NN
and_CC
BSO_NN
enhanced_VBD
As2O3-induced_JJ
ATP_NN
depletion_NN
,_,
delta_NN
psi_NN
-LRB-_-LRB-
m_NN
-RRB-_-RRB-
collapse_NN
,_,
and_CC
apoptosis_NN
._.

Caspase-3_NN
activation_NN
,_,
usually_RB
resulting_VBG
from_IN
delta_NN
psi_NN
-LRB-_-LRB-
m_NN
-RRB-_-RRB-
collapse_NN
,_,
was_VBD
not_RB
always_RB
associated_VBN
with_IN
As2O3-induced_JJ
apoptosis_NN
._.

As2O3_NN
induced_VBD
PML_NN
-LRB-_-LRB-
promyelocytic_JJ
leukemia_NN
-RRB-_-RRB-
protein_NN
degradation_NN
but_CC
did_VBD
not_RB
modulate_VB
expression_NN
of_IN
cell_NN
cycle-related_JJ
proteins_NNS
,_,
including_VBG
c-myc_NN
,_,
retinoblastoma_NN
protein_NN
,_,
cyclin-dependent_JJ
kinase_NN
4_CD
,_,
cyclin_NN
D1_NN
,_,
and_CC
p53_NN
,_,
or_CC
expression_NN
of_IN
differentiation-related_JJ
antigens_NNS
._.

CONCLUSIONS_NNS
:_:
Substantial_JJ
growth_NN
inhibition_NN
and_CC
apoptosis_NN
without_IN
evidence_NN
of_IN
differentiation_NN
were_VBD
induced_VBN
in_IN
most_JJS
malignant_JJ
lymphocytic_JJ
cells_NNS
treated_VBN
with_IN
1-2_CD
microM_NN
As2O3_NN
._.

As2O3_NN
may_MD
prove_VB
useful_JJ
in_IN
the_DT
treatment_NN
of_IN
malignant_JJ
lymphoproliferative_JJ
disorders_NNS
._.

